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Available online 1 December 2015Approximately 30million people currently livewithHIVworldwide and the incidence of stress-related disorders,
such as post-traumatic stress disorder (PTSD), is elevated among people livingwithHIV as compared to those liv-
ing without the virus. PTSD is a severely debilitating, stress-related psychiatric illness associatedwith trauma ex-
posure. Patientswith PTSDexperience intrusive and fearfulmemories aswell asﬂashbacks andnightmares of the
traumatic event(s) for much of their lives, may avoid other people, andmay be constantly on guard for new neg-
ative experiences. This reviewwill delineate the information available to date regarding the comorbidity of PTSD
and HIV and discuss the biological mechanisms whichmay contribute to the co-existence, and potential interac-
tion of, these two disorders. Both HIV and PTSD are linked to altered neurobiology within areas of the brain in-
volved in the startle response and altered function of the hypothalamic-pituitary-adrenal axis. Collectively, the
data highlighted suggest that PTSD and HIV are more likely to actively interact than to simply co-exist within
the same individual. Multi-faceted interactions between PTSD and HIV have the potential to alter response to
treatment for either independent disorder. Therefore, it is of great importance to advance the understanding of
the neurobiological substrates that are altered in comorbid PTSD and HIV such that the most efﬁcacious treat-
ments can be administered to improve both mental and physical health and reduce the spread of HIV.
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. This is an open access article under1. Introduction
Although rarely in the spotlight of the world media, new HIV infec-
tions remain rampant, with 50,000 people newly diagnosed in the
United States and 2.3 million people diagnosed world-wide each year
(Committee on Review Data Systems for Monitoring HIVC and Institute
of Medicine, 2012). The advent of highly active antiretroviral therapy
(ART) dramatically reduced AIDS-related mortality such that approxi-
mately 30 million people currently live with HIV around the globethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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living with HIV (PLWH) are not uniformly responsive to treatment
(Moniz et al., 2014), and poor adherence is a primary factor in subopti-
mal treatment response (Li et al., 2014). Incidents of stressful life events
predict nonadherence and increased odds of virologic failure (Safren
et al., 2003; Mugavero et al., 2009), possibly through avoidant coping
(Martinez et al., 2012). Furthermore, nonadherence in PLWH is particu-
larly prevalent in individuals with a history of early life trauma and
post-traumatic stress disorder (PTSD) (Keuroghlian et al., 2011;
Samuels et al., 2011; Machtinger et al., 2012a; Whetten et al., 2013a).
In fact, PTSD predicts worse HIV-related outcomes for both women
(Katz and Nevid, 2005; Brownley et al., 2015) and men (Yiaslas et al.,
2014). Furthermore, increased emotional reactivity and stress can
raise the risks to the larger community because along with increased
nonadherence, elevated stress and emotional reactivity have been
linked to increased sexual transmission risk behaviors (Machtinger
et al., 2012a; O'Cleirigh et al., 2013; Adedimeji et al., 2014). Therefore,
it is critically important to provide effective treatment for PLWH that
suffer fromPTSD.However, amajor limitation to the effective treatment
of PTSD for PLWH is the lack of understanding regarding the underlying
neurobiology of these disorders by themselves and when they are co-
morbid with one another. HIV is known to disrupt brain function and
alter neuronal communication (Ferrando and Freyberg, 2008;
McIntosh et al., 2015), so it is possible that HIVmodiﬁes neuronal activ-
ity in a manner that is consistent with increased likelihood to manifest
stress-induced disorders such as PTSD. However, it is also plausible
that these disorders are biologically separate, but co-exist in parallel.
This review will delineate the information available to date regarding
the comorbidity of PTSD andHIV and discuss the biologicalmechanisms
whichmay contribute to the co-existence and even interaction of these
two disorders.
2. Epidemiology of PTSD
PTSD manifests after a person has witnessed, has experienced, and/
or has been confronted with a traumatic event (APA, 2013). Symptoms
associated with PTSD include intrusive memories, avoidance of trauma
reminders, numbness, hyper-arousal, and experiencing distorted or
negative thoughts about oneself (APA, 2013). Among all the PTSD
focused-research, the relationship between war veterans and PTSD
has received the most attention. Despite the expansion of knowledge
in regards to PTSD, there is still much to learn about the extent to
which various non-military populations are affected and the bidirec-
tional relationship between PTSD and preexisting conditions.
The cost of treating anxiety disorders including PTSD in the United
Stated alone exceeds $42 billion, which represents half of the costs of
total treatment for nonpsychiatric illness and a third of the cost of
treating mental illness (Greenberg et al., 1999). PTSD is the fourth
most common psychiatric diagnosis, affecting 10% of all men and 18%
of womenwho survive a traumatic event (Breslau et al., 1998a). Of par-
ticular relevance to minority groups, data indicate that women and
African Americans are more likely to be diagnosed with PTSD (Tolin
and Foa, 2006), yet these populations continue to be understudied
with regard to the neurobiology of PTSD.
Risk factors formental illness, such as PTSD, include poverty, low ed-
ucation, homelessness, and exposure to trauma. Low socioeconomic
status (SES) is strongly associatedwith increased exposure to traumatic
events and elevated rates of mental and physical disorders (Breslau
et al., 1991; Fitzpatrick and Boldizar, 1993; Breslau et al., 1998b;
Selner-O'Hagan et al., 1998). Among civilians, economically disadvan-
taged African Americans living within urban environments experience
particularly high levels of trauma (Breslau et al., 1991; Shakoor and
Chalmers, 1991; Fitzpatrick and Boldizar, 1993; Breslau et al., 1998b;
Selner-O'Hagan et al., 1998; Alim et al., 2006; Gillespie et al., 2009). Fur-
thermore, American women and African Americans are more likely to
live in poverty compared to other ethnicities and genders (Kates et al.,2012), and individuals living in impoverished neighborhoods with
high rates of trauma exposure and unstable circumstances, are more
likely to develop mental illnesses and engage in risky behaviors, such
as substance abuse and unprotected sexual activity (Seedat, 2012).
Recently, appreciation has grown for the need for PTSD research to
consider the frequently comorbid condition of HIV. Families living in
low SES are also exposed to more health risks, including HIV (Adler,
2006). Based on current research concerning the American population,
African Americans are most likely to contract HIV, especially African
Americanwomen. In addition to low SES asmentioned above, addition-
al risk factors for HIV include drug use, risky sexual behaviors, traumatic
experiences, and geographical region (Johnson et al., 2014). Additional-
ly, the psychiatric symptoms of PTSD have an adverse inﬂuence on pa-
tient compliance with treatment of concurrent medical illness
(Shemesh et al., 2001; Delahanty et al., 2004; Hilerio et al., 2005;
Sledjeski et al., 2005; Kartha et al., 2008), andmay independently inﬂu-
ence progression and risk for medical disease, (Delahanty et al., 2004;
Kubzansky et al., 2007) such as HIV (Yiaslas et al., 2014; Brownley
et al., 2015).
Further increasing the importance of addressing the comorbidity of
HIV and PTSD is the ﬁnding that approximately 30% of women living
with HIV also suffer from PTSD, an astonishing ﬁve times the incidence
reported among uninfected women (Martinez et al., 2002; Machtinger
et al., 2012b). This elevated prevalence may be related to the high
rates of trauma exposure (Kimerling et al., 1999) because there is a pos-
itive correlation between trauma exposure and the likelihood of PTSD
(Weiss et al., 2013). Typically, it is not one traumatic event that leads
to PTSD but an accumulation of traumatic events. However, certain
events have stronger inﬂuences on one's progression to PTSD
(Brumsey et al., 2013) including the diagnosis of HIV. According to the
American Psychiatric Association's deﬁnition of PTSD, the diagnosis of
HIV qualiﬁes for criterion A trauma for a PTSD diagnosis. Criterion A
trauma is a category that encompasses the direct or indirect exposure
to a traumatic situation that is life threatening (APA, 2013). Although
the diagnosis of cancer, also considered a life-threatening illness, is suf-
ﬁcient to qualify as a criterion A trauma for PTSD diagnosis, the excep-
tionally high prevalence of PTSD in PLWH is not replicated among
individuals with cancer. For example, studies have found that the prev-
alence of PTSD in breast cancer patients is between 2.5–3% (Kessler
et al., 2005; Kwakkenbos et al., 2014), similar to the 12-month preva-
lence of PTSD in females in the US at 5% (Kessler et al., 2005).
Although reports vary, PTSD as a result of a cancer diagnosis is re-
ported to be between 6% to 15% of patients (Abbey et al., 2015), which
is markedly below the 30% of HIV-positive individuals that manifest
PTSD (Martinez et al., 2002; Machtinger et al., 2012b). Whether this is
a result of the biology of either disease state or a differential impact of
the socio-cultural connotation of each disease state, is unknown. How-
ever, it is known that of those who are HIV positive and have been ex-
posed to a traumatic event, PLWH who met criteria for PTSD classiﬁed
their diagnosis of HIV as the most traumatic event because of the expe-
rience of being diagnosed with an illness that can be life threatening
(Olley et al., 2005; Olley et al., 2006). Furthermore, in addition to in-
creasing the risk of PTSD, the duration of HIV infection has been
shown to intensify PTSD symptoms (Rzeszutek et al., 2015) suggesting
that these conditions not only co-occur but interact.
3. Expression of PTSD symptoms in the context of HIV
TheDSM-5diagnostic criteria for PTSD include twenty symptomsdi-
vided across four symptom clusters of intrusive re-experiencing (5
symptoms), effortful avoidance (2 symptoms), negative alterations in
cognitions and mood (7 symptoms) and increased arousal and reactiv-
ity (6 symptoms)(APA, 2013). Additionally, trauma exposure itself is as-
sociated with a range of symptoms often including, but not limited to,
those identiﬁed in the current DSM PTSD criteria. Further, variations
in trauma-related symptom presentations have implications for level
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response to treatment (Shea et al., 2010). For example, re-experiencing
symptoms are the “hallmark” manifestation of PTSD and characteristi-
cally contain an exaggerated fear component. While avoidance symp-
toms may not be as easily apparent as re-experiencing or
hyperarousal symptoms, they frequently contribute to long-termmain-
tenance of symptoms. Avoidance of trauma reminders often includes
avoidance of treatment, which may be especially pronounced with
exposure-based psychotherapies (Lunney and Schnurr, 2007; Schnurr
and Lunney, 2008). In the case of HIV comorbid with PTSD, symptoms
of avoidance may be particularly detrimental because PTSD-associated
avoidance may underlie reduced ART adherence in people with diag-
nosed PTSD (Brief et al., 2004; Nel and Kagee, 2011; Samuels et al.,
2011; Whetten et al., 2013b) and those reporting recent traumas
(Machtinger et al., 2012a). Furthermore, emotional numbing and de-
tachment can reduce the number of patient opportunities to beneﬁt
from social support, a signiﬁcant aid to recovery from PTSD (Andrews
et al., 2003) and control of HIV (Breet et al., 2014).
Patterns of symptoms may be expected to vary over the course of
time following trauma exposure, with fear and avoidance of speciﬁc
trauma cues likely presenting ﬁrst, followed by a more generalized
avoidance and symptoms of depressed mood, which is often comorbid
with PTSD symptoms (Lanius et al., 2002). Hyperarousal symptoms
can often lead to more generalized impairments in function either due
to sleep disturbance, or more frequently, anger issues and subsequent
occupational problems. In addition, a recent study of physiological reac-
tivity in a sample with recurrent trauma exposure found that individ-
uals with multiple traumas showed less reactivity compared to those
with a single trauma (McTeague et al., 2010). The evidence suggests
that trauma responses may present as different “subtypes” or “proﬁles”
of illness. The heterogeneity of psychological outcomes of trauma, byFig. 1. Proposed overlap of PTSD and HIV. The multidirectional relationships between trauma,
sponse have been well described in the literature. HIV has also been demonstrated to impact t
quirement for the diagnosis of PTSD and HIV diagnosis if sufﬁcient to meet the criteria for a cr
demonstrated in both humans and animalmodels. The impact of HIV on startle responsivity has
ments of the interaction of trauma andHIV on fear-potentiated startle. 3) The use of fear-potent
thiswork has not yet been extended to PLWH. 4) The impact of trauma and chronic stress on glu
is beginning to be appreciated. Function of the glucocorticoid receptor (GR) as a transcription fa
resting or baseline conditions, the glucocorticoid receptor resides in the cytosol bound to the co-
stressor exposure and the release of glucocorticoids (GC), GCs bind to the GR and Fkbp5 dissoci
complex into the nucleus where the GR can act as a transcription factor. C) Under conditions of
Fkbp5may prevent binding of Fkbp4 and thereby inhibit translocation, even in the presence of
ing as a transcription factor. 5) The role of glucocorticoid receptor function in fear-conditioned
function, this may be a mechanism by which HIV and trauma interact to alter PTSD symptomsnature, implicates the involvement of several divergent neural systems
in the underlying neurobiology of trauma-related symptomatology
(Frewen and Lanius, 2006). In addition, individual differences in one's
neurobiological makeupmay also contribute to the variability observed
in patient presentations following trauma exposure (Yehuda, 1997).
The high comorbidity of HIV and PTSD and the treatment implications
have been recognized recently in publications aimed at informing
ﬁrst-line medical professionals in the care and management of this vol-
atile comorbidity (Tavakkoli et al., 2014; Brezing et al., 2015). Given the
heterogeneity of PTSD, psychobiological metrics that provide insight to
the underlying biological systems that have been impacted, may be es-
sential to adequate treatment of PTSD variants. Such a progression in
the assessment and treatment of PTSD co-morbid with HIV is in line
with the ResearchDomain Criteria (RDoC)which advocate using neuro-
biological phenotypes to appropriately attend to psychopathology
(Cuthbert and Insel, 2013).
4. Neurobiology of PTSD: startle response
Although there is little understanding of the neurobiology of PTSD
within the context of HIV (Blank et al., 2013), the neurobiology of
PTSD has been a topic of intense study over the past two decades
(Nemeroff et al., 2006; Jovanovic and Ressler, 2010), and a framework
of underlying biological substrates can be constructed from these previ-
ous ﬁndings (Fig. 1). In this section and the following sections, we dis-
cuss the biological components presented in the ﬁgure which may
provide insight into the link between HIV and PTSD.
Dysregulated fear responses are one of the hallmark symptoms of
PTSD and can be objectively measured using biological methods, such
as brain imaging or psychophysiological tests such as startle
responsivity. Neuroimaging studies have shown that the brainglucocorticoid receptor function, post-traumatic stress disorder (PTSD), and the startle re-
he individual components of these interactions. 1) Trauma exposure is an established re-
iterion A trauma. 2) The impact of trauma exposure on fear-potentiated startle has been
been assessed in rodentmodels. To date, there have not been preclinical or clinical assess-
iated startle as a biomarker for PTSDhas been established inHIV uninfected individuals but
cocorticoid receptor function has beenwell characterized. The impact ofHIV on this system
ctor is dependent on translocation from the cytoplasm to the nucleus of the cell. A) Under
chaperone Fkbp5 and other proteinswhich harbor the receptor in the cytosol. B) Following
ates from the complex. This allows Fkbp4 to bindwhich promotes the translocation of the
high stress, disease state, or genetic vulnerability that result in excessive Fkbp5 expression,
GCs. This inhibition would promote glucocorticoid resistance and prevent the GR from act-
startle is a developing area of research and given the inﬂuence of HIV and trauma on GR
and exacerbate the individual impact of each condition.
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amygdala, show hyperactivation in PTSD subjects compared to controls
(Liberzon andMartis, 2006; Shin et al., 2006). The amygdala, part of the
limbic system located in the temporal lobe of the brain, is an integral
part of the fear circuitry (Davis et al., 1993; LeDoux, 2000). Because
the amygdala is one of the neural structures that has been found to be
hyperactive in PTSD (Shin et al., 2006), fear conditioning methods pro-
vide focused laboratory tools for testing exaggerated fear symptoms in
trauma-exposed individuals. In humans, the acoustic startle response
provides an ideal translational tool to investigate fear conditioning, be-
cause the amygdala is directly connected with the startle circuit (Davis,
1992). The startle response can be further parsed to determine if deﬁcits
are at the level of conditioning, discrimination, or extinction; each of
which have distinct neural circuitry. PTSD patients often show overgen-
eralization of fear and in tandem an inability to inhibit fear responses in
the presence of safety. To this end, early studies with Vietnam and Gulf
War veterans found enhanced fear conditioning in PTSD (Morgan et al.,
1996; Grillon et al., 1998). Furthermore, two meta-analyses using fear
conditioning found that patients with anxiety disorders showed greater
levels of fear responses compared to healthy controls (Lissek et al.,
2005; Duits et al., 2015). Knowledge about the neurobiology of fear
and the startle response indicates that impaired fear inhibition may be
a speciﬁc biomarker of PTSD that could be a valuable clinical metric
(Jovanovic et al., 2010).
Fear conditioning is based on a simple Pavlovian conditioningmodel
in which a neutral conditioned stimulus (CS, for example, a light) is
paired with an aversive unconditioned stimulus (US, for example, elec-
tric shock). After a number of pairings, the association is formed so that
the CS alone elicits the conditioned response (CR, for example, a fear re-
sponse). This basic laboratory model can be evaluated with fear-
potentiated startle and is used in animal as well as human research to
investigate mechanisms of fear acquisition. Fear-potentiated startle is
the relative increase in the startle magnitude elicited in the presence
of CS+ that was previously paired with a US. This basic model is used
in animal as well as human research to investigate mechanisms of fear
expression (Jovanovic and Ressler, 2010). Recent data indicate that
both PTSD symptoms and fear-potentiated startle are associated with
inﬂammation in traumatized individuals (Michopoulos et al., 2015),
suggesting a further neurobiological link between PTSD and HIV.5. Neurobiology of HIV and co-morbid anxiety disorders
With respect to HIV and PTSD neurobiology, little work has consid-
ered the impact of HIV or comorbid HIV and PTSD on the startle re-
sponse, and the available research is limited to rodent studies. If we
expand beyond startle responses to sensorimotor gating and the
broader category of anxiety-like behaviors, a wealth of preclinical liter-
ature exists linking HIV proteins to themanifestation of anxiety-like be-
haviors. Rodent work has demonstrated an effect of the HIV protein
gp120 on fear conditioning (Pugh et al., 2000; Fitting et al., 2006a).
HIV proteins, Tat and glycoprotein 120, both have direct effects on sen-
sorimotor gaiting when injected into the hippocampus during the neo-
natal period (Fitting et al., 2006c, 2008b, Fitting et al., 2007), and similar
effects are produced when adult rats are exposed to intrahippocampal
Tat, such that sensorimotor gating is impaired (Fitting et al., 2006a).
Further studies have revealed effects of HIV proteins on hippocampal
morphology (Fitting et al., 2008a; Fitting et al., 2008b) and dopaminer-
gic transmission (Moran et al., 2012;Moran et al., 2013). Examination of
the behavioral patterns of female HIV-1 transgenic rats which express
seven of the nine HIV-related proteins, reveal profound anxiety-like be-
havior as well as depressive-like behavior and altered social behavior
(Nemeth et al., 2014). Although it is not known if all the HIV proteins
can independently induce anxiety-like behavior, Tat has been demon-
strated to have a direct role in precipitation of anxiety behaviors (Paris
et al., 2014).Aside from these studies that help to characterize HIV's effect on be-
havior, it has been demonstrated that HIV can exert effects in the brain
through inﬂammation. Although HIV does not infect neurons, HIV viral
proteins can cross the blood brain barrier and lead to neuroinﬂamma-
tion (Dohgu et al., 2011). IL-6 levels are increased in the cerebrospinal
ﬂuid of patients with HIV-associated neurocognitive disorder (HAND),
the primary neurocognitive disorder in PLWH, and remained increased
compared to controls 12 weeks after starting ART (Airoldi et al., 2012).
Activation of central nervous system monocytes has been suggested as
HIV's primary mechanism for causing neuroinﬂammation. When
monocytes are active, they express a high level of CD14, but a pro-
inﬂammatory subset of monocytes (~10%) express CD16 on their sur-
face (Belge et al., 2002). This pro-inﬂammatory monocyte population
is increased in up to 40% of patients with HIV infection (Pulliam et al.,
2004). Additionally, the virus may infect and subsequently activate mi-
croglia within the central nervous system; their activation can lead to
the release of cytotoxins and neuronal and astrocyte injury (Kaul
et al., 2001; Lipton and Gendelman, 1995). The neuronal injury due to
these inﬂammatory cytokines, chemokines, and excitotoxic substances
released by themicroglia has been hypothesized to contribute to the pa-
thology found in HAND (Glass et al., 1995). Furthermore, microglial ac-
tivation and cytokine expression has been linked to themanifestation of
anxiety-like and depressive-like behaviors in rodent models of other
neurodegenerative conditions such as cardiac arrest and cardiopulmo-
nary resuscitation (Neigh et al., 2009) and microembolic stroke
(Nemeth et al., 2012). This evidence of neuroinﬂammation provides in-
sight as to how HIV can affect the brain. A speciﬁc connection between
the neuroinﬂammation brought on by HIV and psychiatric illness is the
strong correlation between levels of IL-6 (as previouslymentioned to be
elevated in HIV patients) and psychological stress and anxiety/depres-
sion (Fumaz et al., 2012).
Collectively, these data suggest thatwhile we cannot undervalue the
inﬂuence of stress on themanifestation of PTSD associatedwithHIV, it is
essential that we also consider the potential contribution of HIV-related
neurobiological alterations which may render the system more vulner-
able to stress. Neurological disorders are common among those infected
with HIV and include cognitive, motor, and behavioral deﬁciencies
(Atluri et al., 2015). HIV and its byproducts have been demonstrated
to disrupt circuits of the basal ganglia and other neurological compo-
nents and cause neuropsychiatric symptoms (Berger & Arendt, 2000;
Pugliese et al., 2005). Several studies that included neuroimaging tech-
niques have demonstrated the impact of HIV on cognition, motor skills,
and behavior. For instance, a study assessing positron emission tomog-
raphy (PET) scans in PLWH suggests that a decrease in dopaminergic
function has the potential to contribute to cognitive dysfunction
(Chang et al., 2008). In addition, PET scans have been used to link
HIV-related depression to dysregulated serotonergic function
(Hammoud et al., 2010). Evidence of HIV-induced structural changes
has also been reported such as reduced cortical and subcortical volumes
in PLWH (Cohen et al., 2010). These changes can possibly lead to neural
loss, therefore, potentially explainingmotor, cognitive, and affective be-
havior impairments in HIV patients.
6. Neurobiology of PTSD and HIV: HPA axis
The hypothalamic-pituitary-adrenal (HPA) axis mediates the body's
response to a stressor and is named to describe its major component
parts. The HPA axis response culminates with release of glucocorticoids
(GCs), primarily cortisol in humans, from the adrenal glands into the cir-
culation where all organs can be impacted.
Although adaptive in the short term, if the stress response becomes
chronic due to repeated exposure to stressors or does not properly ex-
tinguish due to a traumatic stressor, the result is a sustained increase
in the level of stress hormones and the initiation of pathological changes
such as affective disorders and PTSD (McEwen, 2008). The HPA axisme-
diates the stress response, which culminates when ACTH is humorally
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The primary peripheral role of GCs is to release stored energy, primarily
throughmobilization of glycogen aswell as gluconeogenesis. This chain
of events that characterizes the HPA axis response typically takes sever-
al minutes to fully engage and activation of the HPA axis is eventually
reduced through negative feedback via stimulation of GC receptors
within the hippocampus, hypothalamus, and anterior pituitary
(Jacobson and Sapolsky, 1991).With respect to PTSD, the glucocorticoid
pathway has been implicated in PTSD-induced changes in the brain
(Logue et al., 2015), and manipulation of glucocorticoids has been pro-
posed for treatment of PTSD (Yehuda et al., 2015). Previous studies
have also demonstrated dysfunction of the HPA axis in people living
with HIV (Kumar et al., 2003; Zapanti et al., 2008; Patterson et al.,
2013; Chrousos and Zapanti, 2014). Some studies indicate that HIV pa-
tients have higher cortisol levels compared to non-infected controls
(Membreno et al., 1987, Chrousos and Zapanti, 2014). In addition, glu-
cocorticoids have been demonstrated to directly inﬂuence HIV replica-
tion (Wiegers et al., 2008). Furthermore, psychosocial interventions in
combination with ART improve treatment response and decrease 24-h
urinary cortisol leading to the hypothesis that the noted reduction in
cortisol following psychosocial intervention is causative in improved
treatment response to ART (Antoni, 2003). These studies suggest that
the HPA axis plays a role in the pathology in both PTSD and HIV
infection.
There are multiple points of potential interaction of HIV with the
HPA axis. Starting with the initiation of the response, HIV proteins
could inﬂuence the action of CRH. In fact, the HIV envelope protein
gp-120 has been implicated in stimulating CRH release from the hypo-
thalamus and subsequently leading to a rise in ACTH (Costa et al.,
2000). This is the same envelope protein that was discussed earlier in
having an effect on fear conditioning (Pugh et al., 2000; Fitting et al.,
2006a). This suggests that the effects that HIV has on fear conditioning
and HPA-axis dysregulation work through a similar mechanism that is
inherent to the protein and persists despite ART. In addition to a
potential overstimulation of ACTH, the adrenal response to ACTH has
also been demonstrated to be enhanced in PLWH. When stimulated
with a synthetic derivative of ACTH, cosyntropin, non-infected subjects
have a much higher increase in cortisol release compared to HIV-
infected patients (Membreno et al., 1987). Collectively, these data sug-
gest that the initiating events of theHPA axis response aremore respon-
sive in PLWH.
HIV proteins also exert inﬂuence over theHPA axis at the level of the
target organ response or through effects on negative feedback by ac-
tions on the glucocorticoid receptor's (GR) afﬁnity and expression
(Norbiato et al., 1998). The GR is a pervasive protein and is present on
nearly every cell in the body. The GR is extremely powerful because it
is a transcription factor affecting thousands of genes that play roles in
mood, cognition, neuropsychiatric disorders, immune function and in-
ﬂammation, cell growth and survival, and energy allocation (Bourke
et al., 2012). Although elevated cortisol levels have been observed in
HIV patients, they systemically appear to be in a hypo-cortisol state.
This observation in HIV patients has been attributed to the reduced af-
ﬁnity of GR to cortisol, leading to a glucocorticoid resistance state
(Norbiato et al., 1998). Subsequently, GR expression is increased as
the body attempts to compensate for the glucocorticoid insensitivity
(Kino and Chrousos, 2004). Inﬂammation due to HIV infection as well
as intrinsic viral proteins have been implicated in the alterations in
GR. With HIV infection comes systemic inﬂammation and the expres-
sion of inﬂammatory cytokines such as IL-2 and IL-4. The combined
presence of these cytokines can lead to a change in GR-binding afﬁnity
and increase in GR number (Kam et al., 1993). In terms of potential
mechanisms, structural protein r of HIV (Vpr) has been observed as a
co-activator of GR and may lead to glucocorticoid hypersensitivity
(Kino and Chrousos, 2004).
The systemic inﬂammation presentwith HIV infectionmay also pro-
vide a potential alternatemechanism for the alterations in the HPA axis.Asmentioned previously, inﬂammatory cytokines are expressed follow-
ing HIV infection. Adults on ARTwere found to have signiﬁcantly higher
concentrations of IL-6 as well as high sensitivity C-reactive protein
(hsCRP), a clinical indicator of systemic inﬂammation, compared to
age-matched controls (Neuhaus et al., 2010) Some of these pro-
inﬂammatory cytokines can stimulate the HPA axis, such as IL-1, IL-6,
and tumor necrosis factor-α (TNF-α) (Bernton et al., 1987; Sapolsky
et al., 1987; Perlstein et al., 1993). IL-1 has the ability to stimulate the
hypothalamus and cause secretion of CRH (Bernton et al., 1987;
Sapolsky et al., 1987)while IL-6 and TNF-α lead to an increase in plasma
levels of ACTH. By stimulating the HPA axis, more cortisol will be pro-
duced and observed as the subsequent hypercortisolism found in
many HIV patients.
Recently, genetic markers have been discovered that interact with
early childhood abuse to increase risk for PTSD symptoms. Speciﬁcally,
polymorphisms of the FKBP5 gene (which encodes a co-chaperone
that regulates the GR) have been associated with PTSD symptoms
(Binder et al., 2008; Mehta et al., 2011). In addition, FKBP5 has been
shown to change in PLWH (Tatro et al., 2009) and to respond
differentially to stress in a rodent model of HIV (Panagiotakopoulos
et al., 2015). This gene is involved in regulating cortisol feedback func-
tion (Binder et al., 2008), the stress hormone mechanism that is one
of the most frequently reported trauma-related neurobiological alter-
ations (Yehuda, 2009). Heightened cortisol reactivity in response to
psychosocial stress has been observed in victims of physical and sexual
childhood abuse (Heim et al., 2000), and exaggerated suppression of
HPA axis activity following administration of dexamethasone, a cortisol
analog, has been a consistent ﬁnding associated with a diagnosis of
PTSD (Yehuda et al., 1993; Yehuda, 2009). Recent studies indicate that
this effect is strongest in individuals with higher genetic risk,
i.e., carriers of the FKBP5 risk allele (Binder et al., 2008). Although
other mediators of the GR response are candidates for modulation
of HIV and PTSD effects on HPA axis reactivity, FKBP5 is one of the
best characterized to date and offers an illustration of the range of
levels at which GR function, and thereby HPA axis reactivity, can be
modulated.
Taken together, these studies suggest that HPA dysregulations are
long-term consequences of trauma that are associated with genetic
risk for PTSD. Furthermore, the glucocorticoid pathways may be further
impacted by HIV independent of stress as evidenced by rodent research
(Panagiotakopoulos et al., 2015). The potential importance of the HPA
axis in HIV-related pathology extends beyond PTSD because the GR
has anti-inﬂammatory capacity, and disruption of this pathway could
contribute to HIV-associated chronic inﬂammation. This relationship is
highlighted by a recent study that reported that women with comorbid
HIV and PTSD were more likely to develop shingles suggesting height-
ened disruption of the immune system (Sinayobye et al., 2015). In addi-
tion, the HPA axis, and more speciﬁcally the GR, has an established role
in cognitive impairment which is an increasing concern for PLWH
(Rubin et al., 2015).7. Conclusions
Collectively, the data highlighted here suggest that PTSD andHIV are
more likely to actively interact than to simply co-exist within the same
individual.While HIV and PTSDhave similar risk factors and the order of
manifestation can vary, once present in combination, these two condi-
tions are positioned to create a feed-forward cycle of interaction at
both the behavioral and neurobiological levels (Fig. 1). These multi-
faceted interactions have the potential to alter response to treatment
for either independent disorder. Therefore, it is of great importance to
advance the understanding of the neurobiological substrates that are al-
tered in comorbid PTSD and HIV such that the most efﬁcacious treat-
ments can be administered to improve both mental and physical
health as well as reduce the spread of HIV.
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